Tag Archives: LGND

A Director at Ligand Pharma (NASDAQ: LGND) is Buying Shares

Today, a Director at Ligand Pharma (LGND – Research Report), Jason Aryeh, bought shares of LGND for $22.73K. This is Aryeh’s first Buy trade following 14 Sell transactions. In addition to Jason Aryeh, 2 other LGND executives reported Buy trades

H.C. Wainwright Thinks Ligand Pharma’s Stock is Going to Recover

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $254. The company’s shares closed yesterday at $113.35, close to its 52-week low of $98.56. Pantginis noted:

H.C. Wainwright Reiterates a Buy Rating on Ligand Pharma (LGND)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ligand Pharma (LGND – Research Report), with a price target of $254. The company’s shares closed yesterday at $120.61, close to its 52-week low of

Analysts’ Top Healthcare Picks: Ligand Pharma (LGND), OpGen Inc (OPGN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ligand Pharma (LGND – Research Report), OpGen Inc (OPGN – Research Report) and Galectin Therapeutics (GALT – Research Report) with bullish sentiments.

H.C. Wainwright Sticks to Their Buy Rating for Ligand Pharma (LGND)

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $281. The company’s shares opened today at $175.99. Pantginis observed: “Valuation and risks to price target achievement.

The SVP, GC & Sec of Ligand Pharma is Exercising Options

Today it was reported that the SVP, GC & Sec of Ligand Pharma (NASDAQ: LGND), Charles Berkman, exercised options to buy 2,000 LGND shares at $14.47 a share, for a total transaction value of $28.94K. Following Charles Berkman’s last LGND